NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

NCT05305989

CompletedPhase 2

Sponsor: Kadmon, a Sanofi Company

Conditions: Chronic Graft-versus-host-disease

Interventions: Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD

Countries: United States

Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

Subjects must have been treated with belumosudil for at least 1 of the following:

* Actively receiving belumosudil on Study KD025-208 or Study KD025-213
* Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term Follow-up will be defined as the period after ending treatment with belumosudil and until a FFS event occurs.
* Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and has received at least 6 months of treatment of belumosudil or is in LTFU

Exclusion Criteria:

* Female subject who is pregnant or breastfeeding
* Subject considered unlikely to adhere to treatment and/or follow protocol in the opinion of the Investigator

Locations (8)

Duarte, California, United States
Stanford, California, United States
St Louis, Missouri, United States
Pittsburgh, Pennsylvania, United States
Austin, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Seattle, Washington, United States